Neurocrine Biosciences
NBIX
143.47
-2.04
-1.40%
Neurocrine Biosciences
US · NBIX
#1162 by market cap
Listed 1970
143.47
-2.04
-1.40%
Live - 5344 symbols - heartbeat 464s ago
· 2026-10-08 07:09
Pre-market
144.49
+0.71%
After-hours
143.47
0.00%
Overnight
143.47
0.00%
- Market cap
- 14.58B
- P/E (TTM)i
- 20.98
- P/Bi
- 3.95
- EPSi
- 4.67
- Div yieldi
- 0.00%
- 52W posi
- 33%
Reader sentiment
Are you bullish or bearish on NBIX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 6 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.8 percentage points.
Institutional ownership
- Held by institutions
- 101.40% -1.78pp
- Institutions
- 941 -6
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund76.21%
Hedge Fund15.49%
Public Company3.47%
Government Pension Fund2.92%
Private Company1.45%
Individual/Insider1.18%
Sovereign Wealth Fund1.14%
Insurance Company0.34%
Family Office/Trust0.16%
Top holders as of 2026-06-30
BlackRock
13.49% · 13.71M sh
J.P. Morgan Asset Management, Inc.
5.92% · 6.02M sh
Dodge & Cox
5.49% · 5.58M sh
Vanguard Capital Management, LLC
5.11% · 5.19M sh
Vanguard Portfolio Management, LLC
4.89% · 4.97M sh
State Street Global Advisors
4.31% · 4.39M sh
AQR Capital Management
3.72% · 3.78M sh
Renaissance Technologies Corp.
2.30% · 2.34M sh
Geode Capital Management, LLC
2.10% · 2.14M sh
Two Sigma Investments, LP
2.04% · 2.08M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 20 buys · 30 sells
| Name | Role | Stake |
|---|---|---|
| Kevin Gorman | Chief Executive Officer | 0.51% |
| Kyle Gano | Chief Business Development and Strategy Officer | 0.15% |
| Gary Lyons | Independent Director | 0.12% |
| Eric Benevich | Chief Commercial Officer | 0.07% |
| Darin Lippoldt | Chief Legal Officer | 0.06% |
| William Rastetter | Independent Chairperson | 0.04% |
| Matthew Abernethy | Chief Financial Officer | 0.04% |
| Richard Pops | Independent Director | 0.04% |
| Eiry Roberts | Chief Medical Officer | 0.04% |
| Julie Cooke | Chief Human Resources Officer | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-13 | Matthew Abernethy | Chief Financial Officer | Automatic Disposition | -2,311 | $157.20 |
| 2026-09-13 | David Boyer | Chief Corporate Affairs Officer | Automatic Disposition | -826 | $157.45 |
| 2026-09-10 | Kevin Gorman | Chief Executive Officer | Sale to Issuer | -7,839 | $156.22 |
| 2026-09-10 | Kevin Gorman | Chief Executive Officer | Other Acquisition | +14,343 | -- |
| 2026-09-10 | Julie Cooke | Chief Human Resources Officer | Sale to Issuer | -1,936 | $156.22 |
| 2026-09-10 | Julie Cooke | Chief Human Resources Officer | Other Acquisition | +3,587 | -- |
| 2026-09-10 | Eric Benevich | Chief Commercial Officer | Sale to Issuer | -3,386 | $156.22 |
| 2026-09-10 | Eric Benevich | Chief Commercial Officer | Other Acquisition | +6,275 | -- |
| 2026-09-10 | Jude Onyia | Chief Scientific Officer | Sale to Issuer | -1,936 | $156.22 |
| 2026-09-10 | Jude Onyia | Chief Scientific Officer | Other Acquisition | +3,587 | -- |
| 2026-09-10 | Darin Lippoldt | Chief Legal Officer | Sale to Issuer | -2,419 | $156.22 |
| 2026-09-10 | Darin Lippoldt | Chief Legal Officer | Other Acquisition | +4,483 | -- |
| 2026-09-10 | Kyle Gano | Chief Business Development and Strategy Officer | Sale to Issuer | -4,380 | $156.22 |
| 2026-09-10 | Kyle Gano | Chief Business Development and Strategy Officer | Other Acquisition | +8,117 | -- |
| 2026-09-10 | Matthew Abernethy | Chief Financial Officer | Sale to Issuer | -2,709 | $156.22 |
| 2026-09-10 | Matthew Abernethy | Chief Financial Officer | Other Acquisition | +5,020 | -- |
| 2026-09-10 | David Boyer | Chief Corporate Affairs Officer | Sale to Issuer | -1,936 | $156.22 |
| 2026-09-10 | David Boyer | Chief Corporate Affairs Officer | Other Acquisition | +3,587 | -- |
| 2026-09-10 | Sanjay Keswani | Chief Medical Officer | Sale to Issuer | -2,112 | $156.22 |
| 2026-09-10 | Sanjay Keswani | Chief Medical Officer | Other Acquisition | +3,914 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:09:44 · For reference only, not investment advice and not tailored to your situation.